Evidence map›Paper›PMID 39649165›Full record

ArticleResearch square2024

Revisiting the Plasmodium falciparum druggable genome using predicted structures and data mining.

Karla P Godinez-Macias, Daisy Chen, J Lincoln Wallis, Miles G Siegel, Anna Adam, Selina Bopp, Krypton Carolino, Lauren B Coulson, Greg Durst, Vandana Thathy and 39 more

Abstract readPreprint
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

49 authors.

Karla P Godinez-MaciasUniversity of California, San Diego.
Daisy ChenUniversity of California, San Diego.
J Lincoln WallisPanorama Global.
Miles G SiegelLgenia.
Anna AdamMMV Medicines for Malaria Venture.
Selina BoppHarvard T.H. Chan School of Public Health.
Krypton CarolinoUniversity of California, San Diego.
Lauren B CoulsonUniversity of Cape Town.
Greg DurstLgenia.
Vandana ThathyColumbia University Irving Medical Center.
Lisl EsherickMassachusetts Institute of Technology.
Madeline A FarringerHarvard T.H. Chan School of Public Health.
Erika L FlanneryNovartis (United States).
Barbara ForteUniversity of Dundee.
Tiqing LiuUniversity of California, San Diego.
Luma Godoy MagalhaesUniversity of Dundee.
Anil K GuptaCalibr-Skaggs Institute for Innovative Medicines.
Eva S IstvanWashington University School of Medicine.
Tiantian JiangUniversity of California, San Diego.
Krittikorn KumpornsinCalibr-Skaggs Institute for Innovative Medicines.
Karen LobbLgenia.
Kyle McLeanMassachusetts Institute of Technology.
Igor M R MouraUniversidade de São Paulo.
John OkomboColumbia University Irving Medical Center.
N Connor PayneHarvard T.H. Chan School of Public Health.
Andrew PlaterUniversity of Dundee.
Srinivasa P S RaoNovartis (United States).
Jair L Siqueira-NetoUniversity of California, San Diego.
Bente A SomsenTropIQ Health Sciences.
Robert L SummersHarvard T.H. Chan School of Public Health.
Rumin ZhangGlobal Health Drug Discovery Institute.
Michael K GilsonUniversity of California, San Diego.
Francisco-Javier GamoGlobal Health Medicines R&D.
Brice CampoMMV Medicines for Malaria Venture.
Beatriz BaragañaUniversity of Dundee.
James DuffyMMV Medicines for Malaria Venture.
Ian H GilbertUniversity of Dundee.
Amanda K LukensHarvard T.H. Chan School of Public Health.
Koen J DecheringTropIQ Health Sciences.
Jacquin C NilesMassachusetts Institute of Technology.
Case W McNamaraCalibr-Skaggs Institute for Innovative Medicines.
Xiu ChengGlobal Health Drug Discovery Institute.
Lyn-Marie BirkholtzUniversity of Pretoria.
Alfred W BronkhorstTropIQ Health Sciences.
David A FidockColumbia University Irving Medical Center.
Dyann F WirthHarvard T.H. Chan School of Public Health.
Daniel E GoldbergWashington University School of Medicine.
Marcus C S LeeWellcome Centre for Anti-Infectives Research.
Elizabeth A WinzelerUniversity of California, San Diego.

Funding

Defining the resistome in P. falciparum: evolution and mechanismR01AI169892 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Daniel E. Goldberg, Elizabeth A Winzeler · 2023 to 2026
$4.4M
Plasmodium Protein Kinase Focused Antimalarials DiscoveryR01AI172066 · NIAID · UNIVERSITY OF CENTRAL FLORIDA · PI DEBOPAM CHAKRABARTI, NATHANAEL Schiander GRAY · 2022 to 2026
$3.9M
Graduate Training Program in BioinformaticsT32GM139790 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BAFNA, VINEET, GAASTERLAND, THERESA · 2021 to 2025
$2.1M
Hotspotting Cardiometabolic Disparities for Simulated Advances in Population CareR01AG052533 · NIA · HEALTHPARTNERS INSTITUTE · PI WESTGARD, BJORN CHRISTOPHER · 2018 to 2021
$2.0M
NIAID NIH HHS R01 AI169892NIAID NIH HHS R01 AI172066NIA NIH HHS R01 AG052533NIGMS NIH HHS T32 GM139790
6 · The paper itself

Abstract

The identification of novel drug targets for the purpose of designing small molecule inhibitors is key component to modern drug discovery. In malaria parasites, discoveries of antimalarial targets have primarily occurred retroactively by investigating the mode of action of compounds found through phenotypic screens. Although this method has yielded many promising candidates, it is time- and resource-consuming and misses targets not captured by existing antimalarial compound libraries and phenotypic assay conditions. Leveraging recent advances in protein structure prediction and data mining, we systematically assessed the

Indexed as

druggable genomemalaria data compendiumPlasmodium blood stage targets

Identifiers

PMID39649165
PMCPMC11623766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.